Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 7/20 | 1.00 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.76 |
| ▸ | EYA3 | Q99504 | 5/20 | 0.76 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.76 |
| ▸ | TTR | P02766 | 4/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | PGR | P06401 | 2/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.76 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | EYA2 | O00167 | 1/20 | 0.76 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.76 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.76 |
| ▸ | USP2 | O75604 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21373258 | 0.89 | CYP2C19 (0.79) | CYP2C19SLC22A12EYA3NR1H4CYP2C9 | |
| SCHEMBL25815022 | 0.88 | CYP2C19 (0.79) | CYP2C19SLC22A12EYA3NR1H4CYP2C9 | |
| Benzbromarone SCHEMBL6761161 | 0.88 | SLC22A12 (0.93) | CYP2C19SLC22A12EYA3NR1H4CYP2C9 | |
| SCHEMBL1287556 | 0.86 | CYP2C19 (1.00) | CYP2C19SLC22A12EYA3NR1H4CYP2C9 | |
| SCHEMBL6336171 | 0.86 | NR1H4 (0.79) | CYP2C19SLC22A12EYA3NR1H4CYP2C9 | |
| Benzbromarone SCHEMBL19205474 | 0.86 | SLC22A12 (1.00) | CYP2C19SLC22A12EYA3NR1H4CYP2C9 | |
| Benzbromarone SCHEMBL48993 | 0.86 | SLC22A12 (1.00) | CYP2C19SLC22A12EYA3NR1H4CYP2C9 | |
| Benzbromarone SCHEMBL29361528 | 0.86 | SLC22A12 (1.00) | CYP2C19SLC22A12EYA3NR1H4CYP2C9 | |
| SCHEMBL18058593 | 0.86 | CYP2C19 (0.81) | CYP2C19SLC22A12EYA3NR1H4CYP2C9 | |
| SCHEMBL1288110 | 0.86 | CYP2C19 (0.75) | CYP2C19SLC22A12EYA3NR1H4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4245752-A2 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | Techfields Inc (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-2170826-B1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | TECHFIELDS INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | J-PHARMA CO., LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | J-PHARMA CO., LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20160272653-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | TECHFIELDS PHARMA CO., LTD. (CN) | 2016-09-22 | — | — | US | disclosed |
| US-9371284-B2 | Pro-drugs of NSAIAS with very high skin and membranes penetration rates and their new medicinal uses | TECHFIELDS PHARMA CO., LTD. (CN) | 2016-06-21 | — | — | US | disclosed |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| WO-2012048058-A2 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2012-04-12 | — | — | WO | disclosed |
| US-20100172960-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | PREMIER RESEARCH INTERNATIONAL, LLC | 2010-07-08 | — | — | US | disclosed |
| US-20100172960-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | PREMIER RESEARCH INTERNATIONAL, LLC | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005750-B2 | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action | SLCO2B1, SLCO2A1, SLC10A6 | CYP2C19 269/4885SLC22A12 19/4885EYA3 4828/4885 |
| US-20100172960-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | MYLK2, ALPI, SLC2A2 | CYP2C19 4043/4885SLC22A12 341/4885EYA3 2215/4885 |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | SLCO2B1, SLCO2A1, SLC10A6 | CYP2C19 269/4885SLC22A12 19/4885EYA3 4828/4885 |
| US-20160272653-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | MYLK2, ALPI, SLC2A2 | CYP2C19 4043/4885SLC22A12 341/4885EYA3 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.